Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00557856 · ClinicalTrials.gov registry record · Phase 1
A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 10
- Study locations
NCT00557856 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Pfizer. The registered enrollment target is 70 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (65% lower). The trial reports 10 study locations across 4 states.
The verdict
NCT00557856, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to test the safety and effectiveness of PF-03446962 when given as a single agent. Tumors require new blood vessels to support their ability to grow and to spread (metastasize). New treatments aimed at preventing these blood vessels have the ability to improve the clinical management of cancer.
Conditions Studied
Interventions
- DRUG PF-03446962
Study Locations (10)
Other
- S.C Diagnostica Radiologica 2 - Milan
- S.C. Chirurgia Generale Indirizzo Oncologico 1 (epato-gastro-pancreatica) - Milan
- S.C. Medicina Oncologica I, Fondazione IRCCS Istituto Nazionale Tumori - Milan
- Dipartimento di Medicina - Milan
- UO di Oncologia ed Ematologia, Istituto Clinico Humanitas-Humanitas Cancer Center - Rozzano (MI)
- Seoul National University Hospital / Department of Internal Medicine - Seoul
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
- Vanderbilt University Medical Center - Nashville
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
South Carolina
- Medical University of South Carolina, Hollings Cancer Center - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2007-11 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00557856
The ClinicalTrials.gov registry entry for NCT00557856 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (65% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which PF-03446962 is the first listed.
NCT00557856 reports 10 study locations spanning 4 distinct geographic areas - top geographies include Other, Tennessee, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00557856 about?
NCT00557856 is a clinical study titled "A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors". The purpose of this study is to test the safety and effectiveness of PF-03446962 when given as a single agent. Tumors require new blood vessels to support their ability to grow and to spread (metastasize). New treatments aimed at preventing these blood vessels have the ability to improve the clinica...
What is the current status of trial NCT00557856?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2007-11. Estimated completion is 2013-03.
What conditions does trial NCT00557856 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT00557856?
The interventions under investigation include: PF-03446962 (DRUG).
Who is sponsoring clinical trial NCT00557856?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00557856 being conducted?
This trial has 10 study locations across Pennsylvania, South Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.